Kaya Holdings (KAYS) Shares Outstanding (Diluted Average) (2017 - 2025)
Kaya Holdings (KAYS) recorded quarterly Shares Outstanding (Diluted Average) of $78.1 million in Q3 2025, up 83.05% quarter-over-quarter from $42.7 million in Q2 2025, and up 221.03% on a YoY basis from $24.3 million in Q3 2024.
Kaya Holdings (KAYS) Shares Outstanding (Diluted Average) (2017 - 2025) Analysis & Trends
Kaya Holdings' Shares Outstanding (Diluted Average) history runs 9 years deep, the most recent figure standing at $78.1 million for Q3 2025.
- In Q3 2025, Shares Outstanding (Diluted Average) rose 221.03% year-over-year to $78.1 million; the TTM figure through Sep 2025 stood at $78.1 million (up 221.03% YoY), while the FY2024 annual figure was $257.7 million, up 26.49% from the prior year.
- Shares Outstanding (Diluted Average) was $78.1 million for Q3 2025 at Kaya Holdings, up from $42.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $257.7 million in Q4 2024 to a low of $14.3 million in Q1 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $90.2 million across 5 years, with a median of $70.2 million in 2021.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) soared 1283.91% in 2023, then plunged 83.07% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $72.2 million in 2021, then slumped by 79.15% to $15.0 million in 2022, then surged by 1253.82% to $203.7 million in 2023, then increased by 26.49% to $257.7 million in 2024, then tumbled by 69.7% to $78.1 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $78.1 million (Q3 2025), $42.7 million (Q2 2025), and $42.7 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 103.40 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 228.36 Mn |
| 10 | Kaya Holdings | - | - | 5,370.00 | 78.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 78.10 Mn |
| Jun 30, 2025 | 42.66 Mn |
| Mar 31, 2025 | 42.67 Mn |
| Dec 31, 2024 | 257.72 Mn |
| Sep 30, 2024 | 24.33 Mn |
| Jun 30, 2024 | 221.97 Mn |
| Mar 31, 2024 | 185.80 Mn |
| Dec 31, 2023 | 203.74 Mn |
| Sep 30, 2023 | 143.72 Mn |
| Jun 30, 2023 | 22.17 Mn |
| Mar 31, 2023 | 203.75 Mn |
| Dec 31, 2022 | 15.05 Mn |
| Sep 30, 2022 | 14.72 Mn |
| Jun 30, 2022 | 14.72 Mn |
| Mar 31, 2022 | 14.72 Mn |
| Dec 31, 2021 | 72.18 Mn |
| Sep 30, 2021 | 71.03 Mn |
| Jun 30, 2021 | 70.17 Mn |
| Mar 31, 2021 | 14.33 Mn |
| Dec 31, 2020 | 13.16 Mn |